VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
VivoSim Labs announced it received a $5 million milestone payment from Eli Lilly, triggered by the dosing of the first patient in Phase 2 studies for an IBD drug previously sold to Lilly. The company issued guidance anticipating over 500% revenue growth in Fiscal Year 2027, driven by increased adoption of its NAMs models for preclinical safety testing.
Key figures
- Guidance
- over 500% revenue growth in FY2027
- Milestone payment
- $5 million
- Liver model accuracy
- 91%
- Intestine model sensitivity
- >90%
- Potential future milestones
- $45 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.